Form 4 for CTMX CytomX Therapeutics, Inc.
Accepted 2024-03-21 00:00:00 ET · period of report 2024-03-19 · accession 0001610717-24-000177 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-21 | 2024-03-19 | CTMX | Ogden Christopher | SVP, Fin, Accounting | S - Sale | $2.09 | -2,971 | 85.7K | -3% | -$6,209 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-19 | S | D | 2,971 | $2.09 | 85,686 | D | — | — | (F2) Includes 60,310 restricted stock units. |